Sangamo Therapeutics

Quarterly Financials

Values in thousands 2024-12-31 2024-09-30 2024-06-30 2024-03-31
Revenue
$7,551
$49,412
$356
$481
Gross Profit
7,551
49,412
-2,217
-2,045
EBITDA
-23,855
10,631
-33,481
-44,871
EBIT
-25,990
-36,054
-47,397
Net Income
-23,396
10,672
-36,128
-49,089
Net Change In Cash
7,551
49,412
356
481
Free Cash Flow
-3,503
11,644
-26,884
-48,663
Cash
41,918
39,201
27,786
55,333
Basic Shares
201,699
214,325
203,946
180,342

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$57,800
$176,232
$111,299
$110,701
Gross Profit
57,800
-45,325
111,299
110,701
EBITDA
-89,087
-87,427
-180,719
-165,699
EBIT
-98,448
-109,619
-201,281
-183,337
Net Income
-97,941
-257,831
-192,278
-178,297
Net Change In Cash
57,800
176,232
111,299
110,701
Cost of Revenue
-79,682
47,806
Free Cash Flow
-67,406
-245,997
-243,798
-256,529
Cash
41,918
45,204
100,444
178,872
Basic Shares
201,699
174,444
154,345
144,568

Earnings Calls

Quarter EPS
2024-12-31
-$0.11
2024-09-30
$0.04
2024-06-30
-$0.18
2024-03-31
-$0.27